Porton Advanced introduces the MaxCyte ExPERT GTx Flow Electroporation instrument, continuing to provide customers with end-to-end cell and gene therapy CRO & CDMO services [Yahoo! Finance...
MaxCyte, Inc. (MXCT)
Company Research
Source: Yahoo! Finance
to its cell therapy platform, marking the company as the first cell therapy CDMO in China to possess this clinical-grade flow electroporation system. This equipment, known for its exceptional high transfection efficiency and cell viability, is capable of handling flexible transfection volumes and covering the entire process from research to clinical stages and cGMP production. It also seamlessly scales up for large-volume preparations. MaxCyte has already successfully supported the market launch of the world's first CRISPR/CAS9 gene-edited therapeutic, Casgevy. Porton Advanced is equipped with comprehensive cell therapy process equipment that can meet the production needs of various cell types, including cell banking and autologous or allogeneic cell therapy production, while supporting multiple process routes such as viral vector transfection, non-viral vector electroporation, and gene editing, etc. By introducing the MaxCyte technology platform, Porton Advanced has further strengt
Show less
Read more
Impact Snapshot
Event Time:
MXCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MXCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MXCT alerts
High impacting MaxCyte, Inc. news events
Weekly update
A roundup of the hottest topics
MXCT
News
- President of MaxCyte Maher Masoud Buys More Stock [Yahoo! Finance]Yahoo! Finance
- Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect? [Yahoo! Finance]Yahoo! Finance
- Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why [Yahoo! Finance]Yahoo! Finance
- MaxCyte to Participate in William Blair 44th Annual Growth Stock ConferenceGlobeNewswire
- RGA Investment Advisors Q1 2024 Investment Commentary [Seeking Alpha]Seeking Alpha
MXCT
Earnings
- 5/7/24 - Beat
MXCT
Sec Filings
- 6/27/24 - Form 144
- 6/24/24 - Form 4
- 6/20/24 - Form 144
- MXCT's page on the SEC website